Antitumor

Confirmed Antitumor Activity with T-DXd for HER2-Positive Metastatic CRC

Oncology/Hematology > Colon Cancer — Overall response rate approaching 40%, including hard-to-treat RAS-mutant tumors by Charles Bankhead, Senior Editor, MedPage…